Skip to main content
. 2014 Jun 30;35(9):2097–2101. doi: 10.1093/carcin/bgu140

Table III.

Effect sizes for previously published melanoma risk loci in our melanoma GWAS

Ref Gene CHR SNP MA Other studies Our study
P OR P OR
Barrett et al. (15) 1 rs7412746 C 9.0×10−11 0.89 (0.85–0.95) 1.9×10−4 0.86 (0.79–0.93)
Barrett et al. (15) PARP1 1 rs3219090 T 9.3×10−8 0.82 (NA) 0.005 0.89 (0.82–0.97)
Falchi. et al. (14) CASP8 2 rs13016963 A 8.6×10−10 1.14 (1.09–1.19) 0.15 1.06 (0.98–1.15)
Amos et al. (17) CLPTM1L/TERT 5 rs401681 C 0.004 0.73 (0.59–0.91) 0.05 0.93 (0.85–1.00)
Brown et al. (12) MTAP/CDKN2A 9 rs7023329 G 4.0×10−7 0.85 (0.80–0.91) 2.3×10−5 0.85 (0.78–0.91)
Bishop. et al. (13) MTAP 9 rs10757257 G 3.4×10−8 1.23 (1.15–1.30) 3.9×10−5 1.18 (1.09–1.28)
Nan et al. (10) TYR 11 rs1126809* A 2.8×10−7 1.21 (1.13–1.30) 5.6×10−8 1.25 (1.15–1.35)
Brown et al. (12) TYR 11 rs1393350 A 2.4×10−14 1.29 (1.21–1.38) 6.7×10−5 1.20 (1.10–1.32)
Falchi. et al. (14) CCND1 11 rs1485933 A 0.0012 1.11 (1.04–1.18) / /
Falchi. et al. (14) ATM 11 rs1801516 A 3.4×10−9 0.84 (0.78–0.90) 0.03 0.88 (0.78–0.99)
Brown et al. (12) MC1R 16 rs258322 A 2.5×10−27 1.67 (1.52–1.83) 1.6×10−9 1.50 (1.31–1.71)
Gudbjartsson et al. (11) PIGU 20 rs910873 C 9.9×10−16 1.75 (1.53–2.01) 9.8×10−5 1.42 (1.19–1.69)
Gudbjartsson et al. (11) MYH7B 20 rs1885120 G 9.8×10−16 1.78 (1.54–2.04) 7.1×10−5 1.43 (1.20–1.69)
Falchi. et al. (14) MX2 21 rs45430 G 2.9×10−9 0.88 (0.85–0.92) 0.035 0.90 (0.81–0.99)
Bishop. et al. (13) PLA2G6 22 rs132985 C 2.6×10−7 1.23 (1.15–1.30) 2.8×10−5 1.18 (1.10–1.28)

CHR, chromosome; MA, minor allele and also test allele; NA, not available; OR, odds ratio; our study, Harvard and MD Anderson melanoma GWAS; Ref, reference.

*SNP rs1126809 was not included in our GWAS, and we used SNP rs1847134 as substitution, the LD between the two SNPs is 0.96. SNP rs1485933 was not included in our GWAS, nor any SNPs in high linkage disequilibrium with it.